BrightSpring Health Services, Inc. Common Stock Q1 2026 Earnings Call Summary

Moby Intelligence

3 min read

Revenue growth of 26% was driven by broad-based momentum across both Pharmacy and Provider segments, supported by high-quality care metrics and patient satisfaction.
Pharmacy Solutions performance was bolstered by a 30% increase in specialty script growth and the addition of 4 exclusive ultra-narrow Limited Distribution Drugs (LDDs).
Provider Services growth of 28% was significantly aided by the integration of acquired Amedisys and LHC branches, which contributed $79 million in revenue during the quarter.
Adjusted EBITDA margin improved by 70 basis points year-over-year, primarily attributed to favorable product mix and realized operational efficiencies across the organization.
Management emphasized a disciplined operating model that focuses on high-acuity patients in lower-cost home and community settings to reduce total system costs.
The divestiture of the Community Living business for $811 million allowed for significant deleveraging, bringing the leverage ratio down to 2.27x from 2.99x, with a pro forma leverage of 2.40x after accounting for upcoming tax payments.

Full-year 2026 guidance was updated to reflect expected total revenue between $14.725 billion and $15.225 billion, excluding the divested Community Living business.
Management expects the acquired Amedisys and LHC assets to contribute approximately $30 million in adjusted EBITDA during their first year of integration.
The company anticipates a total 2026 revenue impact of approximately $175 million from the Inflation Reduction Act (IRA) within the Home and Community Pharmacy segment.
Strategic focus remains on expanding the chronic specialty infusion portfolio and scaling value-based care initiatives, including applications for the new LEAD ACO program.
Operational efficiency targets include further cost-to-fill reductions in pharmacy and the deployment of AI-driven automation for intake and revenue cycle processes.

The sale of the Community Living business resulted in approximately $100 million in cash taxes to be paid out in the second quarter of 2026.
Home and Community Pharmacy revenue declined 9% due to the expected $50 million IRA impact and a strategic decision to exit uneconomic customer contracts.
Management noted that while they are underweight in chronic specialty infusion, this represents a significant geographic and therapeutic expansion opportunity.
The company maintains a long-term leverage target in the mid-2s, providing flexibility for future disciplined M&A and capital structure optimization.